Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Randomized Study of Recombinant Human Growth Hormone in Patients on Chronic Hemodialysis or Peritoneal Dialysis
This study is currently recruiting patients.
Sponsored by: | FDA Office of Orphan Products Development Vanderbilt University Medical Center
|
---|---|
Information provided by: | FDA Office of Orphan Products Development |
Purpose
OBJECTIVES: I. Assess the clinical safety and long term effects of recombinant human growth hormone on a defined range of nutritional indices in malnourished chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
Condition | Treatment or Intervention |
---|---|
Kidney Failure, Chronic |
Drug: growth hormone |
MedlinePlus related topics: Kidney Failure
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Crossover Assignment
Expected Total Enrollment: 60
Study start: December 1999
PROTOCOL OUTLINE: This is a randomized, double blind, placebo-controlled, cross-over study. Prior to randomization each patient's protein and calorie intake is assessed and optimized as possible. Patients are randomized to receive either placebo or recombinant human growth hormone subcutaneously every other day for 6 months. At the end of this 6 month period, patients undergo a 4 week washout period. After the washout period, patients are crossed-over to the alternate regimen for an additional 6 months followed by another 4 week washout period.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
PROTOCOL ENTRY CRITERIA: --Disease Characteristics--
--Patient Characteristics--
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |